GLEIF
14.4.2021 09:57:11 CEST | Business Wire | Press release
The Global Legal Entity Identifier Foundation (GLEIF) has welcomed the first commercial demonstration of Legal Entity Identifiers (LEIs) embedded within digital certificates by the China Financial Certification Authority (CFCA). Simultaneously, GLEIF confirms that CFCA, which is a member of the GLEIF Certification Authorities (CA) Stakeholder Group, is the newest Validation Agent in the Global LEI System and the inaugural CA to sign up for the Validation Agent role.
These developments by CFCA follow the recent launch of the GLEIF CA Stakeholder Group, created as a platform for GLEIF to collaborate with CAs and Trust Service Providers (TSPs) on the coordination and promotion of a global approach to LEI usage across digital identity products. CFCA’s advances are significant because they are the earliest reported successes aligned to the direction of this industry initiative, which is aimed at achieving a critical mass of LEIs embedded within digital certificates.
Stephan Wolf, CEO of GLEIF comments: “This progress by CFCA on both fronts is very welcome as it moves us one step closer to broad LEI usage in digital certificates globally. Realizing the goal of universal LEI usage in digital identity products will be an important step in enhancing trust and creating innovation opportunities across private sector digital identity management applications. Digital certificates linked by an LEI to verified, regularly updated and freely available entity reference data held within the Global LEI System are easier to manage, aggregate and maintain. The result will be significant efficiencies and far less complexity for certificate owners and the provision of greater transparency for all users of the internet and participants within digital exchanges.”
CFCA demo: Using LEIs to link PDF digital certificates to entity reference data in the central GLEIF database
CFCA has become the first market participant to successfully demonstrate a commercial use case of LEIs being embedded in a digital certificate, specifically within the digital certificate issuance process for PDF documents. CFCA’s TrustSign® PDF software supports digital certificate signing and the demo shows the LEI displayed for users alongside certificate properties inside the software.
CFCA’s TrustSign® software digitally stamps a document with a Digital Business Stamp, which embeds an LEI in accordance with ISO 17442-2. When the document is opened and certificate properties are displayed, the LEI is shown and a link provided, via the GLEIF LEI Lookup API, to the trusted, free and easily accessible entity reference data associated with that LEI, held within the central GLEIF database.
Naijin Lu, from CFCA’s Strategic Development Department, comments: “Incorporating LEI into our digital identity products brings many benefits to certificate users, while being very helpful in constructing a digital identity ecosystem. By using GLEIF API for real-time online verification of LEI-related legal entity information, the advantages of digital certificate and LEI can be well integrated in the practice of digital identity to create a better digital identity authentication experience. We are excited to bring forward the first market-based demo of its kind, which proves that the combination of LEI and digital identity products has a bright future. In the future, we will actively explore other application scenarios of LEI in digital identification field, such as vLEI. “
Prior to CFCA’s demo, and in 2019 and 2020 consecutively, GLEIF had brought forward a Proof of Concept when it published its prior year reports with its LEI embedded within the digital certificates of GLEIF’s signing executive officers. Both instances were prior to the publication of ISO 17442-2 in August 2020 which standardized the process of embedding LEIs in digital certificates.
CFCA becomes a Validation Agent within the Global LEI System
In a complementary development which shows CFCA’s commitment to facilitating and promoting LEI issuance in digital certificates, the organization has become the first CA to become a Validation Agent in the Global LEI System. It partnered with a China based LEI issuer, China Financial Computerization Corp (CFCC), to enable customers to obtain LEIs and include them within CFCA products. This partnership, made possible under the GLEIF Validation Framework, provides CFCA customers with a ‘one-stop-shop’ for obtaining their LEIs alongside their identity authentication and information security services.
The Validation Agent Framework, announced by GLEIF in September 2020 , enables institutions to improve their customer experience, accelerate client lifecycle management and reduce costs by using ‘business-as-usual’, KYC onboarding procedures to facilitate LEI issuance for their clients.
Wolf concludes: “The swift and successful integration of the LEI into CFCA’s TrustSign® software is a hugely exciting innovation, which we hope will be a catalyst for other similar demos related to LEI usage in digital certificates to emerge. It shows what is possible thanks to ISO 17442-2 and demonstrates the LEI’s unique value in this important use case. GLEIF is happy to confirm CFCA as not only our newest Validation Agent within the Global LEI System, but also as the first CA to take up that role. Its partnership with CFCC has made that possible. As momentum builds for the LEI to be used outside of regulatory use cases, thanks to recognition of the opportunity and efficiencies it can offer to the private sector, provision of Validation Agent services by a wide range of key actors in the digital ID management and verification ecosystem will be critical to servicing scaled-up LEI demand and simplifying LEI issuance.
We are excited to learn more about CFCA’s advances through their engagement in the GLEIF CA Stakeholder Group. Their developments get this digital identity industry collaboration off to an incredibly strong start. We look forward to working with CFCA and all members of the CA Stakeholder Group as we jointly set out to advance trust and transparency within digital identity products.”
GLEIF welcomes CAs and TSPs to join and participate in the CA Stakeholder Group’s quarterly meetings. For more information or to join the group, please email info@gleif.org
- ENDS -
Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images
Relevant link
https://www.gleif.org/en
Source:
Global Legal Entity Identifier Foundation, St. Alban-Vorstadt 5, 4052 Basel, Switzerland
Chairman of the Board: Steven Joachim, CEO: Stephan Wolf
Commercial-Register-No.: CHE-200.595.965, VAT-No.: CHE-200.595.965MWST
LEI: 506700GE1G29325QX363
http://bit.ly/1OXTYLo | http://bit.ly/1Me7uZx | GLEIF Blog: http://bit.ly/1LylXkn http://bit.ly/1LylXkn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005319/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
